Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

(2016) Yongkun Sun et al.   Journal of Hematology & Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

(2015) Adrian G. Sacher et al.   CANCER

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial

(2015) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

(2015) Martin Reck et al.   LUNG CANCER

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer

(2014) Seigo Miyoshi et al.   International Journal of Clinical Oncology

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

(2014) Tomoya Kawaguchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Caveolin-1 knockdown is associated with the metastasis and proliferation of human lung cancer cell line NCI-H460

(2012) Yang Song et al.   BIOMEDICINE & PHARMACOTHERAPY

Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations

(2011) S. Matsuura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

(2010) Hiroshige Yoshioka et al.   Journal of Thoracic Oncology

Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice

(2009) D. Tassinari et al.   ANNALS OF ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2009) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

(2008) K Tamura et al.   BRITISH JOURNAL OF CANCER

Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell-Depleted SCID Mice

(2008) H. Ogino et al.   CLINICAL CANCER RESEARCH